A novel approach for the detection and genetic analysis of live melanoma circulating tumor cells

• Published in: PloS one 2015-03, Vol.10 (3), p.e0123376
• Main Authors: Xu, Melody J, Cooke, Mariana, Steinmetz, David, Karakousis, Giorgos, Saxena, Deeksha, Bartlett, Edmund, Xu, Xiaowei, Hahn, Stephen M, Dorsey, Jay F, Kao, Gary D
• Format: Article
• Language: English
• Subjects: Adenoviridae - genetics; Adult; Aged; Area Under Curve; Assaying; Biotechnology; Bladder cancer; Blood; Brain cancer; Cancer metastasis; Cancer therapies; Cell culture; Cell Line, Tumor; Feasibility studies; Female; Fluorescence; Fluorescent Antibody Technique; Gene mutation; Genetic analysis; Genetic aspects; Genetic research; Genetic Vectors - genetics; Genetic Vectors - metabolism; Genomes; Green fluorescent protein; Humans; Image processing; Kinases; Linear Models; Male; Medicine; Melanoma; Melanoma - metabolism; Melanoma - pathology; Metastases; Metastasis; Middle Aged; Mutation; Neoplasm Metastasis; Neoplastic Cells, Circulating - metabolism; Neoplastic Cells, Circulating - pathology; Oncology; Patients; Penicillin; Pilot Projects; Proteins; Proto-Oncogene Proteins B-raf - genetics; Radiation therapy; ROC Curve; Senescence; Sensitivity; Sensitivity analysis; Telomerase; Telomerase - metabolism; Tumor cells; Tumors
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0123376

Circulating tumor cell (CTC) detection and genetic analysis may complement currently available disease assessments in patients with melanoma to improve risk stratification and monitoring. We therefore sought to establish the feasibility of a telomerase-based assay for detecting and isolating live melanoma CTCs. The telomerase-based CTC assay utilizes an adenoviral vector that, in the presence of elevated human telomerase activity, drives the amplification of green fluorescent protein. Tumor cells are then identified via an image processing system. The protocol was tested on melanoma cells in culture or spiked into control blood, and on samples from patients with metastatic melanoma. Genetic analysis of the isolated melanoma CTCs was then performed for BRAF mutation status. The adenoviral vector was effective for all melanoma cell lines tested with sensitivity of 88.7% (95%CI 85.6-90.4%) and specificity of 99.9% (95%CI 99.8-99.9%). In a pilot trial of patients with metastatic disease, CTCs were identified in 9 of 10 patients, with a mean of 6.0 CTCs/mL. At a cutoff of 1.1 CTCs/mL, the telomerase-based assay exhibits test performance of 90.0% sensitivity and 91.7% specificity. BRAF mutation analysis of melanoma cells isolated from culture or spiked control blood, or from pilot patient samples was found to match the known BRAF mutation status of the cell lines and primary tumors. To our knowledge, this is the first report of a telomerase-based assay effective for detecting and isolating live melanoma CTCs. These promising findings support further studies, including towards integrating into the management of patients with melanoma receiving multimodality therapy.